Labcorp — Apr 30, 2026 release

(Dollars in billions, except per share data) Previous Updated 2026 Guidance 2026 Guidance Low High Low High Revenue Labcorp Enterprise (1)(2) $14.61 $14.79 $14.65 $14.80 Growth (3) 4.7% 6.0% 5.0% 6.1% Diagnostics Laboratories $11.42 $11.53 $11.43 $11.52 Growth (3) 5.0% 6.0% 5.1% 5.9% Biopharma Laboratory Services (4) $3.19 $3.25 $3.22 $3.27 Growth (3) 3.0% 5.0% 3.8% 5.4% Adjusted EPS $17.55 $18.25 $17.70 $18.35 Free Cash Flow $1.24 $1.36 $1.24 $1.36 (1) 2026 Updated guidance includes an impact from foreign currency translation of 0.4%. (2) Enterprise level revenue is presented net of intercompany transaction eliminations. (3) Growth based on 2025 Enterprise revenue of $14.0 billion, Diagnostics revenue of $10.9 billion, and Biopharma Laboratory Services revenue of $3.1 billion. (4) 2026 Updated guidance includes an impact from foreign currency translation of 1.5%. 7 Use of Adjusted Measures The company has provided in this press release and accompanying tables “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company’s operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as